<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval
Image Overlay - CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

November 8, 2019

CAR-T Therapy for Refractory Thyroid Cancer Receives IND Approval

AffyImmune Therapeutics announced FDA approval of their investigational new drug (IND) for AIC100, a CAR-T cell therapy aimed at treating patients with advanced thyroid cancer. The first-in-human phase I study will be sponsored by Weill Cornell Medical Center. Yourway is anticipating a surge in clinical trials exploring these advanced therapies, and is prepared to support any customers for their unique needs.

 Back to Index
Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?